logo

Atossa Genetics, Inc. (ATOS)



Trade ATOS now with
  Date
  Headline
6/26/2018 8:07:06 AM Atossa Genetics Opens Its Phase 2 Study Of Topical Endoxifen To Treat Mammographic Breast Density
6/20/2018 8:07:22 AM Atossa Genetics Completes All Dosing And Clinical Visits In Its Phase 1 Study Of Topical Endoxifen In Men
6/14/2018 8:08:35 AM Atossa Genetics Appoints Two Additional Executives To Its Strategic Advisory Board
5/14/2018 8:13:10 AM Atossa Genetics Q1 Net Loss $1.87 Mln Or $0.71/Shr Vs Loss $1.7 Mln Or $5.40/Shr Last Year
5/8/2018 8:07:09 AM Atossa Genetics Regains NASDAQ Compliance
5/7/2018 8:28:48 AM Atossa Genetics Reminds Investors Of Today’s Deadline To Be A Shareholder Of Record
5/3/2018 8:16:39 AM Atossa Genetics Forms Strategic Advisory Board
4/30/2018 8:17:20 AM Atossa Genetics Gets Approval From The Swedish Medical Products Agency For Phase 2 Topical Endoxifen Study
4/16/2018 8:16:54 AM Atossa Genetics Urges Shareholders To Vote On Two Of Most Recent Proposals That Still Remain Open From April 12
4/12/2018 8:08:25 AM Atossa Genetics Enrolls First Cohort Of Eight Subjects In Endoxifen Study In Men
3/27/2018 8:34:53 AM Atossa Genetics Appoints Per Hall As Scientific Advisor
  
 
>